200 related articles for article (PubMed ID: 37099077)
1. Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study.
Mao Y; Huang L; Ruan H; Guo Y; Ni S; Ling Y
Support Care Cancer; 2023 Apr; 31(5):303. PubMed ID: 37099077
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
3. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
4. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
[TBL] [Abstract][Full Text] [Related]
7. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
8. Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.
Di Rocco A; Cuneo A; Di Rocco A; Merli F; De Luca G; Petrucci L; Ansuinelli M; Penna D; Rotondo F; Rigolin GM; Giaimo M; Re F; Farcomeni A; Martelli M; Foà R
Leuk Lymphoma; 2021 Apr; 62(4):828-836. PubMed ID: 33274677
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
11. Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis.
Cao HH; Wang LL; Geng CK; Mao WW; Yang LL; Ma Y; He M; Zhang R; Zhou YY; Liu LQ; Hu XJ; Yu JX; Yang L; Shen XF; Yin LF; Gu XZ; Shen ZL
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4921-4930. PubMed ID: 32432755
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
Front Immunol; 2022; 13():858021. PubMed ID: 35432352
[TBL] [Abstract][Full Text] [Related]
13. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
[TBL] [Abstract][Full Text] [Related]
14. Integrating CAR-T cell therapy into the management of DLBCL: what we are learning.
Martino M; Canale FA; Porto G; Verduci C; Utano G; Policastro G; Germanò J; Alati C; Santoro L; Imbalzano L; Pitea M
Expert Opin Biol Ther; 2023; 23(12):1277-1285. PubMed ID: 38078446
[TBL] [Abstract][Full Text] [Related]
15. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
Kong D; Ping N; Gao X; Zou R; Wang P; Wu D; Jin Z; Qu C
Front Immunol; 2023; 14():1200748. PubMed ID: 37292195
[TBL] [Abstract][Full Text] [Related]
17. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.
Garcia-Recio M; Wudhikarn K; Pennisi M; Alonso-Trillo R; Flynn J; Shouval R; Afuye AO; Silverberg ML; Batlevi CW; Dahi P; Devlin S; Giralt SA; Halton E; Ruiz J; Maloy M; Mead E; Palomba ML; Santomasso B; Sauter CS; Scordo M; Shah GL; Perales MA
Transplant Cell Ther; 2021 Mar; 27(3):233-240. PubMed ID: 33781518
[TBL] [Abstract][Full Text] [Related]
18. The Patient Symptom Experience After Tisagenlecleucel and Lisocabtagene Maraleucel CAR T-Cell Therapy for Lymphoma.
Andersen L; Baker KM; Difilippo H; Meghani SH; Porter D; Deng J
Semin Oncol Nurs; 2024 Apr; 40(2):151614. PubMed ID: 38443220
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
Dang X; Ye S; Zhou L; Lu Y; Li P; Liang A; Qian W
Cytotherapy; 2023 Jun; 25(6):573-577. PubMed ID: 36456447
[TBL] [Abstract][Full Text] [Related]
20. Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study.
Cheng R; Scippa K; Locke FL; Snider JT; Jim H
Oncol Ther; 2022 Jun; 10(1):123-141. PubMed ID: 34778941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
